Advertisement

Pathology of Breast Cancer

Subtypes, Receptors, Biologic Markers, and Staging
Published:October 17, 2022DOI:https://doi.org/10.1016/j.suc.2022.08.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schnitt S.J.
        • Brogi E.
        • Chen Y.Y.
        • et al.
        American registry of pathology expert opinions: the spectrum of lobular carcinoma in situ: diagnostic features and clinical implications.
        Ann Diagn Pathol. 2020; 45: 151481
        • Arps D.P.
        • Jorns J.M.
        • Zhao L.
        • et al.
        Re-excision rates of invasive ductal carcinoma with lobular features compared with invasive ductal carcinomas and invasive lobular carcinomas of the breast.
        Ann Surg Oncol. 2014; 21: 4152-4158
        • Krings G.
        • Bean G.R.
        • Chen Y.Y.
        Fibroepithelial lesions; The WHO spectrum.
        Semin Diagn Pathol. 2017; 34: 438-452
        • WHO Classification of Tumors Editorial Board
        WHO classification of tumors.
        5th edition. International Agency for Research on Cancer, Lyon2019 (Breast tumors)
        • Page D.L.
        • Salhany K.E.
        • Jensen R.A.
        • et al.
        Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma.
        Cancer. 1996; 78: 258-266
        • Li X.
        • Xu Y.
        • Ye H.
        • et al.
        Encapsulated papillary carcinoma of the breast: A clinicopathological study of 49 cases.
        Curr Probl Cancer. 2018; 42: 291-301
        • Oldenhuis C.N.
        • Oosting S.F.
        • Gietema J.A.
        • et al.
        Prognostic versus predictive value of biomarkers in oncology.
        Eur J Cancer. 2008; 44: 946-953
      1. Amin M.B. Edge S.B. Greene F.L. AJCC cancer staging manual. 8th edition. Springer, New York2017
        • Allison K.H.
        • Hammond M.E.H.
        • Dowsett M.
        • et al.
        Estrogen and progesterone receptor testing in breast cancer: american society of clinical oncology/college of american pathologists guideline update.
        Arch Pathol Lab Med. 2020; 144: 545-563
        • Wolff A.C.
        • Hammond M.E.H.
        • Allison K.H.
        • et al.
        Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline focused update.
        Arch Pathol Lab Med. 2018; 142: 1364-1382
        • Peppercorn J.
        • Perou C.M.
        • Carey L.A.
        Molecular subtypes in breast cancer evaluation and management: divide and conquer.
        Cancer Invest. 2008; 26: 1-10